OFG
KRYS icon

OmniStar Financial Group’s Krystal Biotech KRYS Stock Holding History

OmniStar Financial Group’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,878
Closed -$258K – 131
2025
Q2 		$258K Sell
1,878
-148
-7% -$21.7K 0.19% 103
2025
Q1 		$365K Buy
+2,026
New +$341K 0.29% 92

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

OmniStar Financial Group's KRYS Position: Q3 2025 in Review

OmniStar Financial Group sold out of Krystal Biotech (KRYS) in Q3 2025, closing a stake of 1,878 shares — an estimated $258K sold.

OmniStar Financial Group first reported a position in KRYS in Q1 2025 and held it in 2 quarters. The position peaked at $365K in Q1 2025. 284 funds tracked by Wall St. Rank hold KRYS as of Q3 2025.

  • OmniStar Financial Group reported no remaining Krystal Biotech position as of Q3 2025 after selling out during the quarter.
  • OmniStar Financial Group sold 1,878 Krystal Biotech shares in Q3 2025, an estimated $258K.
  • OmniStar Financial Group first reported a position in Krystal Biotech in Q1 2025 and held it in 2 quarters.
  • OmniStar Financial Group's Krystal Biotech position peaked at $365K in Q1 2025.
  • 284 funds tracked by Wall St. Rank held Krystal Biotech as of Q3 2025.

Based on OmniStar Financial Group's 13F filing for Q3 2025, filed 17 Nov 2025.